0000000000969231

AUTHOR

Glauco Milio

showing 50 related works from this author

Ticlopidine in the Treatment of Multiple Atherosclerotic Arteriopathy: a Strain Gauge Plethysmography and Döppler Spectrum Analysis Evaluation

1987

The effect of ticlopidine was compared with flunarizine in patients with iliac–femoral and / or femoral–popliteal arteriosclerotic arteriopathy accompanied by lesions of the cervical arteries of no haemodynamic significance. In the lower limbs, plethysmography (strain gauge measurements) and Döppler ultrasonography integrated by spectral analysis of the cervical arteries showed qualitative and quantitative improvements of the regional haematic flow. Side-effects were negligible which suggests that ticlopidine is useful in the treatment of multiple arteriosclerotic arteriopathy.

medicine.medical_specialtyPathologyTiclopidineArteriosclerosisCervical ArteryHemodynamics030204 cardiovascular system & hematologyBiochemistry03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineHumansMedicinePlethysmograph030212 general & internal medicineTiclopidineFlunarizineAgedUltrasonographybusiness.industryVascular diseaseBiochemistry (medical)Cell BiologyGeneral MedicineMiddle Agedmedicine.diseasePlethysmographyCardiologysymbolsbusinessDoppler effectBlood Flow VelocityFlunarizinemedicine.drugStrain gauge plethysmographyJournal of International Medical Research
researchProduct

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation base…

2008

Abstract Residual vein thrombosis (RVT) indicates a prothrombotic state and is useful for evaluating the optimal duration of oral anticoagulant treatment (OAT). Patients with a first episode of deep vein thrombosis, treated with OAT for 3 months, were managed according to RVT findings. Those with RVT were randomized to either stop or continue anticoagulants for 9 additional months, whereas in those without RVT, OAT was stopped. Outcomes were recurrent venous thromboembolism and/or major bleeding. Residual thrombosis was detected in 180 (69.8%) of 258 patients; recurrent events occurred in 27.2% of those who discontinued (25/92; 15.2% person-years) and 19.3% of those who continued OAT (17/88…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep veinImmunologyHemorrhageBiochemistryDrug Administration ScheduleSettore MED/15 - Malattie Del SangueDeep vein thrombosioral anticoagulantSecondary PreventionmedicineHumansAgedUltrasonographyVenous ThrombosisFirst episoderesidual vein thrombosisVascular diseasebusiness.industryAnticoagulantHazard ratioAnticoagulantsCell BiologyHematologyMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisConfidence intervalSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemalebusinessBlood
researchProduct

The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication

2006

Aim of the study is to evaluate the effects of Prostaglandin E-1 (PGE-1) in patients with peripheral arterial disease (PAD) at the 2nd b stage Fontaines classification. The study, controlled, single blinded, enrolled 123 patients with intermittent claudication that were randomised in two groups; the first group received a treatment with PGE-1 while the second one received a pentoxifylline-buflomedil association by venous infusion. We evaluated: Pain Free Walking Distance (PFWD), Maximum Walking Distance (MWD), Rest Flow (RF), Peak Flow (PF), Basal (BVR) and Minimal Vascular Resistance (MVR) with a strain gauge plethysmograph, Resting Flow (RF), Peak Flow (PF), time to reach the Peak Flow (t…

AdultMalemedicine.medical_specialtyPyrrolidinesVasodilator AgentsProstaglandinHemodynamicsWalkingSeverity of Illness IndexMicrocirculationchemistry.chemical_compoundInternal medicineLaser-Doppler FlowmetrymedicineHumansPlethysmographAlprostadilPentoxifyllineInfusions IntravenousAgedPharmacologybusiness.industryHematologyGeneral MedicineIntermittent ClaudicationMiddle AgedLaser Doppler velocimetryIntermittent claudicationSurgeryPeripheralPlethysmographyDrug CombinationsTreatment Outcomemedicine.anatomical_structurechemistryRegional Blood FlowExercise TestVascular resistanceCardiologyMolecular MedicineFemaleVascular Resistancemedicine.symptomCardiology and Cardiovascular MedicinebusinessCardiovascular & Hematological Disorders-Drug Targets
researchProduct

Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis

2011

It is well established that physically fit individuals have a reduced risk of developing CVD (cardiovascular disease) and other age-related chronic disorders. Regular exercise is an established therapeutic intervention with an enormous range of benefits. Chronic low-grade systemic inflammation may be involved in atherosclerosis, diabetes and in pathogenesis of several chronic pathological conditions; recent findings confirm that physical activity induces an increase in the systemic levels of a number of cytokines and chemokines with anti-inflammatory properties. The possibility that regular physical exercise exerts anti-inflammation activity, being the interaction between contracting muscle…

Settore MED/09 - Medicina InternaInflammationPhysical exerciseDiseaseSystemic inflammationPathogenesisDrug DiscoveryMyokinemedicineAnimalsHumansExercise Cytokines inflammationEndothelial dysfunctionExercise physiologyExerciseInflammationPharmacologybusiness.industryAge FactorsAtherosclerosismedicine.diseaseExercise TherapyPhysical FitnessImmunologyDisease ProgressionCytokinesmedicine.symptombusinessBiomarkersCurrent Pharmaceutical Design
researchProduct

Antiplatelet treatment in ischemic stroke treatment.

2009

Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot. Immediate treatment with antiplatelet drugs such as aspirin may prevent new clots from forming and hence improve recovery after stroke. Several studies have evaluated the role of one antiplatelet agent, aspirin, in reducing stroke severity. The International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In thi…

medicine.medical_specialtySettore MED/09 - Medicina InternaTiclopidineBrain IschemiaInternal medicineDrug DiscoveryAntithromboticmedicineHumanscardiovascular diseasesPlatelet activationTiclopidineStrokeAspirinAspirinbusiness.industryGeneral Medicinemedicine.diseaseClopidogrelSurgeryClopidogrelStrokemedicine.anatomical_structureToxicityCardiologyantiplatelets strokeprevention treatmentbusinessPlatelet Aggregation Inhibitorsmedicine.drugArteryCurrent topics in medicinal chemistry
researchProduct

Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response

2011

Calciphylaxis is a severe “vascular ossification–calcification,” associated with a very high mortality rate that involvesarterial wall, venular wall, and nerves resulting in ischemia and necrosis of skin, subcutaneous fat, visceral organs,and skeletal muscles. Sodium thiosulfate has recently been used as a novel treatment option for calciphylaxisbecause of its dual role as an antioxidant and a chelator. Multiple case reports demonstrated that such therapy hasresulted in pain relief and healing of skin ulceration. We report a case of calciphylaxis of large severity that had anambiguous response to sodium thiosulfate treatment (improvement of symptomatology and skin lesions, improve-ment of b…

medicine.medical_specialtyNecrosisSettore MED/09 - Medicina InternaIschemiaThiosulfatesSodium thiosulfateCritical Care and Intensive Care MedicineGastroenterologySubcutaneous fatSeverity of Illness IndexAntioxidantschemistry.chemical_compoundFatal OutcomeInternal medicineSeverity of illnessmedicineHumansChelating AgentsThiosulfateCalciphylaxisbusiness.industryCalciphylaxisGeneral MedicineMiddle Agedmedicine.diseasethiosulfate calciphylaxisSurgeryTreatment OutcomechemistryNephrologyFemalemedicine.symptombusinessBlood parameters
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Response to letter by Drs. Mohammed Abbas, Maria Sessa, and Francesco Corea

2006

RISKbusiness.industryCarotid arteriesINFECTIONCAROTID ATHEROSCLEROSISMedicineGeneral MedicineAnatomybusinessBURDEN
researchProduct

Asymptomatic Carotid Lesions and Aging: Role of Hypertension and Other Traditional and Emerging Risk Factors

2006

Background We evaluated the prevalence of intima-media thickening (IMT) and asymptomatic carotid plaque (ACP) in a group of subjects with or without traditional and/or emerging risk factors (RF). Methods There were 631 subjects (313 male and 318 female) aged between 19 and 97 years, asymptomatic for cerebro- and cardiovascular diseases. The following measurements were used: anamnesis, physical examination, height and sitting blood pressure. Biochemistry variables were also considered: total cholesterol, HDL-C, LDL-C, triglycerides, fibrinogen, high sensitive C-reactive protein, IgG antibodies for Helicobacter pylori (HP), cytotoxic HP, cytomegalovirus and Chlamydia pneumoniae . Finally, an …

medicine.medical_specialtyPathologyPopulationPhysical examinationCerebroFibrinogenGastroenterologyAsymptomaticInternal medicinemedicinecardiovascular diseaseseducationAnamnesiseducation.field_of_studyChlamydiamedicine.diagnostic_testbiologybusiness.industryGeneral MedicineHelicobacter pyloribiology.organism_classificationmedicine.diseasecardiovascular systemmedicine.symptombusinessmedicine.drug
researchProduct

The supraventricular tachycardias: Proposal of a diagnostic algorithm for the narrow complex tachycardias

2013

AbstractThe narrow complex tachycardias (NCTs) are defined by the presence in a 12-lead electrocardiogram (ECG) of a QRS complex duration less than 120ms and a heart rate greater than 100 beats per minute; those are typically of supraventricular origin, although rarely narrow complex ventricular tachycardias have been reported in the literature.As some studies document, to diagnose correctly the NCTs is an arduous exercise because sometimes those have similar presentation on the ECG. In this paper, we have reviewed the physiopathological, clinical, and ECG findings of all known supraventricular tachycardias and, in order to reduce the possible diagnostic errors on the ECG, we have proposed …

Tachycardiamedicine.medical_specialtyBeats per minuteAtrioventricular nodeAtrial flutterDiagnosis DifferentialElectrocardiographyHeart RateInternal medicineTachycardia SupraventricularHumansMedicinecardiovascular diseasesDiagnostic Errorsmedicine.diagnostic_testbusiness.industryAtrial fibrillationmedicine.diseaseAtrioventricular nodeAtrial fibrillationmedicine.anatomical_structureSupraventricular tachycardiaCardiologycardiovascular systemSupraventricular tachycardiaDifferential diagnosismedicine.symptombusinessCardiology and Cardiovascular MedicineElectrocardiographyAlgorithmAlgorithmsAtrial flutterJournal of Cardiology
researchProduct

Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins

2008

Introduction. Superficial venous thrombosis (SVT) has been considered for a long time a limited clinical condition with a low importance, but this approach has changed in recent years, when several studies demonstrated spreading to deep veins occurring from 7.3 to 44%, with high prevalence of pulmonary embolism . Materials and Methods. To evaluate the prevalence of genetic risk factors for VTE in patients suffering from SVT on both normal and varicose vein, and to evaluate their role on spreading to deep veins, we studied 107 consecutive outpatients with symptomatic SVT. Ultrasound examination was performed, and the presence of FV Leiden, Prothrombin G20210A mutation, MTHFR C677T mutation w…

AdultMalemedicine.medical_specialtyAdolescentDeep veinThrombophiliaGastroenterologyVeinsCohort StudiesVaricose VeinsYoung AdultRisk FactorsInternal medicineVaricose veinsmedicinePrevalenceHumansGenetic Predisposition to DiseaseMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisColor-duplex-Ultrasonography Genetic Risk Factors Superficial Venous Thrombosis Venous ThromboembolismVascular diseasebusiness.industryFactor VHematologyMiddle Agedmedicine.diseaseThrombosisSettore MED/11 - Malattie Dell'Apparato CardiovascolarePulmonary embolismVenous thrombosismedicine.anatomical_structureEmbolismMutationFemaleProthrombinRadiologymedicine.symptombusinessPhlebitisPulmonary Embolism
researchProduct

Subclavian Stenosis/Occlusion in Patients with Subclavian Steal and Previous Bypass of Internal Mammary Interventricular Anterior Artery: Medical or …

2004

There are only a few published studies on the association between subclavian steal syndrome and ischemic heart disease. The objective of this report is to evaluate the efficacy of subclavian stenoocclusion treatment in patients with subclavian steal syndrome (SSS) and previous cor- onary bypass. Over the last 8 years we observed 207 patients who underwent left internal mammary artery–intraventricular artery (LIMA–IVA) bypass graft. Of these, 31 patients were affected by steno-occlusion of the homolateral subclavian artery. Ten patients (group 1) showed latent vertebral-SSS and were pharmacologically treated. Seven patients (group 2) had an intermittent vertebral-SSS; four patients were trea…

Malemedicine.medical_specialtyTiclopidinemedicine.medical_treatmentConstriction PathologicSubclavean stenosis/occlusionAnginaSubclavian Steal SyndromeRestenosisRisk FactorsInternal medicinemedicine.arteryAngioplastymedicineHumanscardiovascular diseasesInternal Mammary-Coronary Artery AnastomosisSubclavian arteryAgedAspirinmedicine.diagnostic_testbusiness.industryAngioplastyStentGeneral MedicineMiddle Agedmedicine.diseaseSurgerybody regionssurgical procedures operativeAngiographycardiovascular systemCardiologyPlatelet aggregation inhibitorFemaleStentsSurgeryCardiology and Cardiovascular MedicinebusinessSubclavian steal syndromePlatelet Aggregation InhibitorsAnnals of Vascular Surgery
researchProduct

Hypertension and peripheral arterial hemodynamics.

1995

Sixty uncomplicated hypertensive patients (30 stable and 30 borderline) were studied, by strain gauge plethysmography, in comparison with 25 normotensive subjects, in order to evaluate the arterial hemodynamics of the lower limbs in essential hypertension and to verify the different pattern in borderline and in stable hypertensives. Resting blood flow, even if slightly decreased in hypertensive groups, did not show significant differences in its mean values; peak flow, instead, was reduced proportionally to the severity of hypertension in all the hypertensive patients, but only in the stable hypertensives was it statistically significant. Minimal vascular resistance showed a similar behavi…

AdultMalemedicine.medical_specialtySystoleHemodynamics030204 cardiovascular system & hematologyEssential hypertension03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineDiastoleInternal medicinemedicinePlethysmographHumans030212 general & internal medicineAgedLegbusiness.industryHemodynamicsBlood flowArteriesMiddle Agedmedicine.diseasePeripheralPlethysmographyEndocrinologymedicine.anatomical_structureHypertensionVascular resistanceCardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryAngiology
researchProduct

Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study

2009

Abstract Background. The optimal duration of Oral Anticoagulant Therapy (OAT) for Deep Vein Thrombosis (DVT) can be tailored by Residual Vein Thrombosis (RVT) (Siragusa S et al. Blood2003;102(11):OC183), a marker able to assess the individual risk for recurrent thrombosis. However, in patients with idiopathic DVT the safety of early interruption of OAT, because of absence of RVT, is still debated. Objective of the study. In the present study, we evaluated the safety of withholding OAT, in patients with idiopathic DVT and without RVT, three months after the index thrombotic episode. Study design. Prospective controlled study with two groups: patients without RVT stopped OAT after 3 months wh…

medicine.medical_specialtyDeep veinImmunologyPopulationThrombophiliaBiochemistrydeep vein thombosis anticoagulationSettore MED/15 - Malattie Del SanguemedicineVeineducationFirst episodeeducation.field_of_studyresidual vein thrombosisbusiness.industrydeep vein thrombosiCell BiologyHematologymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryPulmonary embolismVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs.

2005

Background. Venous ulcers represent an important medical problem due to their high prevalence and consequent sanitary costs. In this study we evaluated the effect of Prostaglandin E-1 (PGE-1), a drug that improves district ischemia, on the healing of venous ulcers. Methods. We performed a randomized, placebo-controlled, single blind study, in which 87 patients, carriers of venous leg ulcers, homogeneous for dimensions and characteristics, were treated for 20 days an with infusion of Prostaglandin E-1 or placebo, in association with a topic therapy. The dimension and the number of the ulcers were determined at the beginning of the treatment and then every 20 days up to 4 months or until tota…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentVasodilator AgentsIschemiaHealing timeProstaglandinPlacebolaw.inventionVaricose Ulcerchemistry.chemical_compoundRandomized controlled triallawMedicineHumansSingle-Blind MethodAlprostadilAgedLegUltrasonography Doppler DuplexWound Healingbusiness.industryMiddle Agedmedicine.diseasedigestive system diseasesSurgeryClinical trialchemistryBaseline characteristicsVenous ulcers Prostaglandine E-1SurgeryFemaleCardiology and Cardiovascular MedicinebusinessProstaglandin EJournal of vascular surgery
researchProduct

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

Il trattamento domiciliare della TVP

2008

terapia domiciliareTrombosi venosaSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Calf veins thrombosis: optimal duration of treatment

2004

researchProduct

Trattamento delle manifestazioni vascolari nella Sclerosi Sistemica e qualità della vita: nuovo protocollo

2005

TRATTAMENTO DELLE MANIFESTAZIONI VASCOLARI NELLA SCLEROSI SISTEMICA E QUALITA’ DELLA VITA: NUOVO PROTOCOLLO
researchProduct

Metabolic therapy in the treatment of chronic critical limbs ischemia: the L-propionyl-carnitine enhances the effects of PGE-1

2005

researchProduct

Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis

2008

Context Patients with suspected deep vein thrombosis ( DVT) of the lower extremities are usually investigated with ultrasonography either by the proximal veins ( 2-point ultrasonography) or the entire deep vein system ( whole- leg ultrasonography). The latter approach is thought to be better based on its ability to detect isolated calf vein thrombosis; however, it requires skilled operators and is mainly available only during working hours. No randomized comparisons are yet available evaluating the relative values of these 2 strategies. Objective To assess if the 2 diagnostic strategies are equivalent for the management of symptomatic outpatients with suspected DVT of the lower extremities.…

Malemedicine.medical_specialtyDeep veinContext (language use)VeinsSettore MED/15 - Malattie Del Sanguelaw.inventionFibrin Fibrinogen Degradation ProductsRandomized controlled triallawD-dimermedicineHumansProspective StudiesUltrasonography Doppler ColorProspective cohort studyAgedVenous ThrombosisFirst episodeLegbusiness.industrydeep vein thrombosiultrasonographyGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryVenous thrombosismedicine.anatomical_structureD-dimerFemaleRadiologybusinessJAMA
researchProduct

Peso dei fattori di rischio nell’evoluzione dell’aterosclerosi preclinica

2007

researchProduct

Asymptomatic carotid lesions and aging: role of hypertension and other traditional and emerging risk factors

2005

ASYMPTOMATIC CAROTID LESIONS AND AGING: ROLE OF HYPERTENSION AND OTHER TRADITIONAL AND EMERGING RISK FACTORS BACKGROUND: We evaluated the prevalence of intima-media thickening (IMT) and asymptomatic carotid plaque (ACP) in a group of subjects with or without traditional and/or emerging risk factors (RF). METHODS: There were 631 subjects (313 male and 318 female) aged between 19 and 97 years, asymptomatic for cerebro- and cardiovascular diseases. The following measurements were used: anamnesis, physical examination, height and sitting blood pressure. Biochemistry variables were also considered: total cholesterol, HDL-C, LDL-C, triglycerides, fibrinogen, high sensitive C-reactive protein, IgG…

carotid stenosiatherosclerosihypertensionSettore MED/09 - Medicina Internarisk factorsSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Immunohistochemical expression of iNOS and eNOS in the venous ulcers related to chronic venous insufficiency (CVI).

2005

researchProduct

Residual vein thrombosis estabilishes the optimal duration of oral anticoagulants for the treatment od DVT

2004

researchProduct

Ischemia critica cronica e vasculopatia ischemica polidistrettuale

2004

researchProduct

Calf vein thrombosis: optimal duration of tretment

2004

researchProduct

Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombo…

2005

researchProduct

SUPERFICIAL VENOUS THROMBOSIS: ROLE OF GENETIC RISK FACTORS ON SPREADING TO DEEP VEINS

2005

researchProduct

La terapia metabolica nel trattamento dell'ischemia critica cronica degli arti inferiori: la L-propionilcarnetina potenzia gli effetti della PGE-1

2004

researchProduct

Trombosi venosa superficiale ed estensione al circolo profondo: ruolo dei fattori di rischio genetici

2005

trombosi venosa superficialeSettore MED/10 - Malattie Dell'Apparato Respiratoriofattori di rischio geneticiSettore MED/15 - Malattie Del Sangue
researchProduct

Calf vein thrombosis: optimal duration of treatment

2004

researchProduct

NO and Chronic Venous Insufficiency (CVI): Immunohistochemical Evaluation of iNOS and eNOS Isofroms in the Venous Ulcers. Clinical and Therapeutical …

2007

researchProduct

Modello di percorso diagnostico e terapeutico per la trombosi venosa superficiale

2012

Trombosi venosa superficiale - Percorsi diagnostico terapeuticiSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Residual Vein Thrombosis Assessment Establishes the Optimal Duration of Oral Anticoagulants in Patients with Idiopathic or Provoked Deep Vein Thrombo…

2005

researchProduct

Immunohistochemical expression of iNOS and metalloproteinases MMP2 and MMP9 in abdominal inflammatory aortic Aneurysms

2007

researchProduct

Moderno approccio alla trombosi venosa superficiale

2010

trombosi venosa superficiale fattori di rischio TEV progressione TVSSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Residual vein thrombosis assessment establishes the otpimal duration of oral anticoagulants in patients with idiopathic or provoked deep vein thrombo…

2004

researchProduct

METABOLIC THERAPY IN THE TREATMENT OF CHRONIC CRITICAL LIMBS ISCHEMIA OF THE LOWER LIMBS. THE L-PROPIONYL-CARNITINE ENHANCES THE EFFECTS OF PGE-1

2005

researchProduct

Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombo…

2004

researchProduct

Superficial venous thrombosis and spreading to deep veins: role of genetic risk factors for venous thromboembolism

2004

genetic risk factorsSuperficial vein thrombosiSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/15 - Malattie Del Sangue
researchProduct

Ischemia critica e connettiviti: presupposti fisiopatologici per un protocollo di trattamento

2006

researchProduct

Aspetti fisiopatologici dell'ulcera venosa

2009

ulcera venosaSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

The effects Prostaglandine E-1 in patients with intermittent claudication

2005

researchProduct

Superficial venous thrombosis: role of genetic risk factors on spreeding to deep veins

2005

researchProduct

Stress ossidativo in pazienti con sclerodermia: effetti dell’iloprost.

2007

researchProduct

Effetti dell’iloprost sulla disfunzione leucocitaria nella sclerodermia.

2007

researchProduct

TROMBOSI PROFONDA SUPERFICIALE ED ESTENSIONE AL CIRCOLO PROFONDO: RUOLO DEI FATTORI DI RISCHIO GENETICI

2005

researchProduct

Effetti emoreologici del trattamento con iloprost in pazienti con fenomeno di Raynaud secondario a sclerodermia.

2006

researchProduct

Rilievi emoreologici nella sclerosi sistemica.

2007

researchProduct